Search Results - "Almond, Lisa M."

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example by Pan, Xian, Abduljalil, Khaled, Almond, Lisa M., Pansari, Amita, Yeo, Karen Rowland

“…Evaluating the safety of primaquine (PQ) during breastfeeding requires an understanding of its pharmacokinetics (PKs) in breast milk and its exposure in the…”
Get full text

PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies by Abla, Nada, Almond, Lisa M., Bonner, Jennifer J., Richardson, Naomi, Wells, Timothy N. C., Möhrle, Jörg J.

“…The urgent need for safe, efficacious, and accessible drug treatments to treat coronavirus disease 2019 (COVID‐19) prompted a global effort to evaluate drug…”
Get full text

Development and application of a PBPK modeling strategy to support antimalarial drug development by Abla, Nada, Howgate, Eleanor, Rowland‐Yeo, Karen, Dickins, Maurice, Bergagnini‐Kolev, Mackenzie C., Chen, Kuan‐Fu, McFeely, Savannah, Bonner, Jennifer J., Santos, Laura G. A., Gobeau, Nathalie, Burt, Howard, Barter, Zoe, Jones, Hannah M., Wesche, David, Charman, Susan A., Möhrle, Jörg J., Burrows, Jeremy N., Almond, Lisa M.

“…Abstract As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash University, physiologically‐based pharmacokinetic (PBPK)…”
Get full text

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19 by Hong, Eunjin, Almond, Lisa M., Chung, Peter S., Rao, Adupa P., Beringer, Paul M.

“…Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor‐tezacaftor‐ivacaftor, are primarily eliminated through…”
Get full text

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling by Rowland Yeo, Karen, Zhang, Mian, Pan, Xian, Ban Ke, Alice, Jones, Hannah M., Wesche, David, Almond, Lisa M.

“…We use a mechanistic lung model to demonstrate that accumulation of chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZ) in the lungs is sensitive…”
Get full text

A tutorial on physiologically based pharmacokinetic approaches in lactation research by Pansari, Amita, Pan, Xian, Almond, Lisa M, Rowland-Yeo, Karen

“…In breastfeeding mothers, managing medical conditions presents unique challenges, particularly concerning medication use and breastfeeding practices. The…”
Get full text

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series by Hong, Eunjin, Li, Regina, Shi, Alan, Almond, Lisa M., Wang, Joshua, Khudari, Amin Z., Haddad, Soumar, Sislyan, Sarkis, Angelich, Marissa, Chung, Peter S., Rao, Adupa P., Beringer, Paul M.

“…Introduction Elexacaftor/tezacaftor/ivacaftor (ETI) treatment is associated with significant improvement in lung function in people with cystic fibrosis…”
Get full text

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model by Almond, Lisa M, Mukadam, Sophie, Gardner, Iain, Okialda, Krystle, Wong, Susan, Hatley, Oliver, Tay, Suzanne, Rowland-Yeo, Karen, Jamei, Masoud, Rostami-Hodjegan, Amin, Kenny, Jane R

“…Using physiologically based pharmacokinetic modeling, we predicted the magnitude of drug-drug interactions (DDIs) for studies with rifampicin and seven CYP3A4…”
Get full text

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women by Ning, Jia, Pansari, Amita, Rowland Yeo, Karen, Heikkinen, Aki T, Waitt, Catriona, Almond, Lisa M

“…Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant…”
Get full text

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing by Wetmore, Barbara A, Allen, Brittany, Clewell, 3rd, Harvey J, Parker, Timothy, Wambaugh, John F, Almond, Lisa M, Sochaski, Mark A, Thomas, Russell S

“…Momentum is growing worldwide to use in vitro high-throughput screening (HTS) to evaluate human health effects of chemicals. However, the integration of…”
Get full text

Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients: Expected Variations in Clearance by Ghobadi, Cyrus, Johnson, Trevor N., Aarabi, Mohsen, Almond, Lisa M., Allabi, Aurel Constant, Rowland-Yeo, Karen, Jamei, Masoud, Rostami-Hodjegan, Amin

“…Background and Objectives: The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that…”
Get full text

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals by Almond, Lisa M., Hoggard, Patrick G., Edirisinghe, Damitha, Khoo, Saye H., Back, David J.

“…Objectives: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide…”
Get full text

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals by Almond, Lisa M., Edirisinghe, Damitha, Dalton, Mark, Bonington, Alec, Back, David J., Khoo, Saye H.

“…Background and Objective Plasma concentrations of nevirapine have been linked to human immunodeficiency virus (HIV) treatment outcome. However, because the…”
Get full text

The relationship between nevirapine plasma concentrations and abnormal liver function tests by Almond, Lisa M, Boffito, Marta, Hoggard, Patrick G, Bonora, Stefano, Raiteri, Riccardo, Reynolds, Helen E, Garazzino, Silvia, Sinicco, Alessandro, Khoo, Saye H, Back, David J, Di Perri, Giovanni

“…Abnormal liver function tests are frequently observed in HIV-infected individuals receiving nevirapine (NVP). Here we investigate the relationship between…”
Get more information

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea by HOGGARD, Patrick G, KEWN, Stephen, KHOO, Saye H, MAHERBE, Anlie, WOOD, Robin, ALMOND, Lisa M, SALES, Sean D, GOULD, Jayne, LOU, Yu, DE VRIES, Corry, BACK, David J

“…Nucleoside analogues are activated to their triphosphates, which compete with endogenous deoxynucleoside triphosphate (dNTP) pools to inhibit HIV reverse…”
Get full text

Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients by Ghobadi, Cyrus, Johnson, Trevor N, Aarabi, Mohsen, Almond, Lisa M, Allabi, Aurel Constant, Rowland-Yeo, Karen, Jamei, Masoud, Rostami-Hodjegan, Amin

“…Background and Objectives: The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that…”
Get full text

Intracellular and plasma pharmacoldnetics of nevirapine in human immunodeficiency virus-infected individuals by ALMOND, Lisa M, EDIRISINGHE, Damitha, DALTON, Mark, BONINGTON, Alec, BACK, David J, KHOO, Saye H

Get full text